Penyakit Paget Tulang

01Pathophysiology

Paget's disease is fundamentally a disorder of bone remodeling in which the normal coupling between osteoclast-mediated resorption and osteoblast-mediated formation becomes chaotic and exaggerated. The disease progresses through three distinct phases, and understanding these phases is what connects the pathology to the clinical presentation.

The initial lytic phase is dominated by overactive, abnormally large osteoclasts that contain far more nuclei than normal (up to 100 nuclei per cell, compared to the usual 3 to 20). These giant osteoclasts resorb bone at a dramatically accelerated rate. On imaging during this phase, you see purely lytic lesions, such as the classic "osteoporosis circumscripta" of the skull or the "blade of grass" (flame-shaped) advancing lytic front in long bones. The reason the osteoclasts behave this way is still debated, but the leading theory involves a combination of genetic susceptibility (mutations in SQSTM1/p62, which regulates NF-kB signaling in osteoclasts) and a possible viral trigger (paramyxovirus nuclear inclusions have been found within pagetic osteoclasts, though this remains controversial).

In response to the excessive resorption, osteoblasts are recruited in large numbers to lay down new bone, which marks the mixed (active) phase. However, because the process is so rapid and disorganized, the new bone that forms is woven bone rather than the normal, mechanically strong lamellar bone. This woven bone is structurally inferior: it is thickened but weak, porous, and prone to deformity. This is why patients develop bowing of the tibia or femur and pathologic fractures despite the bones appearing radiographically "dense."

The late sclerotic (burned-out) phase is dominated by dense, sclerotic bone with minimal active remodeling. Even in this phase, the bone retains its disorganized architecture.

Several clinical features follow directly from this pathophysiology:

• Bone pain results from periosteal stretching by the expanding, deformed bone and from microfractures within structurally weak woven bone.

• Warmth over affected bone is caused by the markedly increased blood flow needed to supply the hypermetabolic remodeling process. In patients with polyostotic (multi-bone) disease, this arteriovenous shunting can be so extensive that it increases cardiac output, potentially causing high-output cardiac failure in elderly patients.

• Hearing loss occurs when pagetic bone encroaches on the structures of the middle or inner ear. This can be conductive (ossicular involvement), sensorineural (cochlear compression by expanding bone), or mixed.

• Skull enlargement and frontal bossing result from expansion of the thickened calvarium, which is why patients classically report that their hats no longer fit.

• The most feared complication is osteosarcoma, which develops in fewer than 1% of patients but carries an extremely poor prognosis. A sudden worsening of pain or a new soft tissue mass in a patient with known Paget's disease should raise immediate concern for malignant transformation.

On bone biopsy (rarely needed clinically), the hallmark is the "mosaic pattern" of cement lines, reflecting the innumerable cycles of disorganized resorption and formation layered upon each other. This finding is pathognomonic.

02Classification and Clinical Manifestation

Paget's disease is classified by the extent of skeletal involvement and by the phase of disease activity:

The most commonly affected bones, in descending order, are the pelvis, lumbar spine, femur, skull, and tibia. Exam vignettes will frequently describe a patient with pain in one of these locations combined with a laboratory profile showing an isolated elevation in alkaline phosphatase.

03Diagnostic Workup

The diagnostic approach to Paget's disease typically begins when a clinician encounters an unexplained elevation in serum alkaline phosphatase on routine blood work. This is the single most important laboratory finding. In a classic exam vignette, you will see an older patient who is either asymptomatic or has chronic bone pain, and the lab panel shows a very high ALP with normal serum calcium and normal serum phosphorus. This triad (high ALP, normal Ca, normal P) is the biochemical signature of Paget's disease and immediately distinguishes it from primary hyperparathyroidism (where calcium is elevated) and from metastatic bone disease (where calcium may also be elevated).

The best initial test is the serum alkaline phosphatase level, which is almost always elevated in clinically active disease and correlates with the extent and activity of bone involvement. If the ALP is elevated and Paget's is suspected, the next step is to obtain plain radiographs of the symptomatic area. X-ray findings are often diagnostic on their own: look for a thickened, coarsened trabecular pattern, cortical thickening, bone enlargement, and the characteristic mixed lytic-sclerotic pattern. In the skull, the classic finding is the "cotton wool" appearance (patchy sclerotic densities). In vertebrae, you may see the "picture frame" vertebra (cortical thickening with a lucent center). In long bones, you may see the "blade of grass" or "flame-shaped" advancing lytic front or bowing deformity.

A technetium-99m bone scan is then used to determine the full extent of skeletal involvement. Bone scan is the most sensitive imaging modality for detecting pagetic lesions, as it identifies areas of increased metabolic activity before structural changes become visible on plain films. This step is important because patients may have asymptomatic involvement at additional sites.

Bone biopsy is the most accurate test and reveals the pathognomonic mosaic pattern, but it is almost never required in clinical practice because the combination of a markedly elevated ALP, normal calcium, and characteristic radiographic findings is sufficient. Biopsy is reserved for cases where there is concern about malignant transformation to osteosarcoma, in which case you would see a destructive lesion with a soft tissue mass rather than the expected pagetic pattern.

An important clinical pearl: because ALP can be elevated from hepatic sources as well as bone, if there is any doubt about the origin of the elevated ALP, you can check bone-specific alkaline phosphatase or use gamma-glutamyl transferase (GGT) as a differentiator. If GGT is normal, the elevated ALP is of bone origin.

04Management and Treatment

Bisphosphonates are the cornerstone of treatment for Paget's disease. They work by inhibiting osteoclast activity and inducing osteoclast apoptosis, which directly targets the fundamental pathologic process. The goal of treatment is to normalize the serum alkaline phosphatase and relieve bone pain.

Zoledronic acid (5 mg as a single intravenous infusion) is the preferred agent because it has the highest potency and the longest duration of remission. Many patients achieve biochemical remission (normalization of ALP) that lasts for several years after a single dose. Before administering zoledronic acid, ensure the patient has adequate calcium and vitamin D levels and a creatinine clearance above 35 mL/min, as bisphosphonates are nephrotoxic and contraindicated in severe renal insufficiency.

For patients who prefer oral therapy, alendronate 40 mg daily for 6 months or risedronate 30 mg daily for 2 months are effective alternatives. Oral bisphosphonates must be taken on an empty stomach with a full glass of water, and the patient must remain upright for at least 30 minutes afterward to prevent esophageal erosion.

Calcitonin (salmon calcitonin, 100 IU subcutaneously daily) is a second-line agent used when bisphosphonates are contraindicated (for example, in patients with severe renal impairment or esophageal disorders). Calcitonin is less potent and has a shorter duration of effect, and patients may develop tachyphylaxis (loss of efficacy with prolonged use due to antibody formation).

Treatment is indicated in the following situations: symptomatic disease (bone pain attributable to Paget's), involvement of weight-bearing bones at risk for fracture or deformity, skull base involvement (risk of hearing loss or cranial nerve compression), planned surgery on pagetic bone (bisphosphonates reduce hypervascularity and bleeding), and hypercalcemia during immobilization.

A common management trap on exams is distinguishing between bone pain (which responds to bisphosphonates) and joint pain from secondary osteoarthritis (which does not respond to bisphosphonates and requires analgesics or joint replacement). If a patient with Paget's disease has persistent pain despite bisphosphonate therapy with normalized ALP, the pain is likely arthritic rather than pagetic.

Monitoring is performed by tracking the serum ALP over time. A falling ALP indicates response to treatment. Most clinicians recheck ALP at 3 to 6 months after treatment and then annually. If the ALP rises again after initial remission, retreatment with bisphosphonates is appropriate.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get questions about Paget's disease wrong is by confusing it with primary hyperparathyroidism. Both conditions present with bone pain and elevated alkaline phosphatase, and both appear in older patients. The discriminating laboratory finding that you must anchor on is the serum calcium: in Paget's disease, calcium is normal; in primary hyperparathyroidism, calcium is elevated. If an exam question gives you elevated ALP with elevated calcium, you are dealing with hyperparathyroidism or malignancy, not Paget's. If the ALP is elevated and the calcium is normal, Paget's should be at the top of your differential.

A second common trap involves the complication of osteosarcoma. The vignette will describe a patient with a long-standing history of Paget's disease who suddenly develops worsening pain, a palpable mass, or a new destructive lesion on imaging. Students may be tempted to attribute this to disease progression, but the correct answer is to suspect secondary osteosarcoma and proceed with biopsy. This is a classic "change in clinical trajectory" question.

Another tested concept is the distinction between bone pain and joint pain in a Paget's patient. A vignette showing persistent pain after adequate bisphosphonate therapy (with a normalized ALP) is pointing you toward secondary osteoarthritis as the cause of pain, and the next step is analgesics or orthopedic referral, not more bisphosphonates.

Students also sometimes forget that Paget's disease can cause high-output cardiac failure in polyostotic disease. A question stem describing an elderly patient with extensive skeletal Paget's who presents with symptoms of heart failure (dyspnea, edema, elevated jugular venous pressure) with a high cardiac output on echocardiography is testing this association.

Finally, be alert to the immobilization and hypercalcemia scenario. A patient with Paget's who becomes immobilized (for example, after a hip fracture) can develop hypercalcemia because bone resorption continues while weight-bearing formation stimulus is lost. The treatment is rehydration, bisphosphonates, and early mobilization.

The core competency being tested across all Paget's questions is pattern recognition: the ability to identify the disease from its biochemical signature (isolated ALP elevation with normal calcium), connect that signature to the correct imaging and biopsy findings, choose bisphosphonates as first-line treatment, and recognize the feared complications (osteosarcoma, high-output heart failure, hearing loss) when they are woven into a clinical scenario.